XENETIC BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
XENETIC BIOSCIENCES, INC. (XBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $51.96 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $51.96K, a 231.34% increase year-over-year.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $11.31K, a 41.24% decline year-over-year.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $14.00K, a 44.25% decline year-over-year.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $15.86K, a 42.42% decline year-over-year.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $64.79K, a 62.29% decline from fiscal 2024.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $171.81K, a 39.31% decline from fiscal 2023.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $283.08K, a 44.65% decline from fiscal 2022.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $511.48K, a 24.62% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $51.96K 10-Q · filed 2026-08-06 | $63.28K 10-Q · filed 2026-08-06 | $77.27K derived: sum of 3 quarters · filed 2026-08-06 | $93.13K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $11.31K 10-Q · filed 2026-05-12 | $25.31K derived: sum of 2 quarters · filed 2026-05-12 | $41.16K derived: sum of 3 quarters · filed 2026-05-12 | $56.85K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $29.85K derived: sum of 2 quarters · filed 2026-03-12 | $45.54K derived: sum of 3 quarters · filed 2026-08-06 | $64.79K 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $15.86K 10-Q · filed 2025-11-12 | $31.54K derived: sum of 2 quarters · filed 2026-08-06 | $50.79K 10-Q · filed 2025-11-12 | $75.90K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $15.68K 10-Q · filed 2026-08-06 | $34.93K 10-Q · filed 2026-08-06 | $60.04K derived: sum of 3 quarters · filed 2026-08-06 | $87.58K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $19.25K 10-Q · filed 2026-05-12 | $44.36K derived: sum of 2 quarters · filed 2026-05-12 | $71.89K derived: sum of 3 quarters · filed 2026-05-12 | $113.99K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $25.11K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $52.64K derived: sum of 2 quarters · filed 2026-03-12 | $94.74K derived: sum of 3 quarters · filed 2026-03-12 | $171.81K 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $27.54K 10-Q · filed 2025-11-12 | $69.63K derived: sum of 2 quarters · filed 2025-11-12 | $146.71K 10-Q · filed 2025-11-12 | $221.28K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $42.10K 10-Q · filed 2025-08-12 | $119.17K 10-Q · filed 2025-08-12 | $193.75K derived: sum of 3 quarters · filed 2025-08-12 | $264.01K derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $77.07K 10-Q · filed 2025-05-13 | $151.65K derived: sum of 2 quarters · filed 2025-05-13 | $221.92K derived: sum of 3 quarters · filed 2025-05-13 | $291.31K derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $74.58K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $144.84K derived: sum of 2 quarters · filed 2025-03-18 | $214.23K derived: sum of 3 quarters · filed 2025-03-18 | $283.08K 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $70.27K 10-Q · filed 2024-11-12 | $139.66K derived: sum of 2 quarters · filed 2024-11-12 | $208.51K 10-Q · filed 2024-11-12 | $327.16K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $69.39K 10-Q · filed 2024-08-13 | $138.24K 10-Q · filed 2024-08-13 | $256.89K derived: sum of 3 quarters · filed 2024-08-13 | $394.26K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $68.85K 10-Q · filed 2024-05-09 | $187.50K derived: sum of 2 quarters · filed 2024-05-09 | $324.87K derived: sum of 3 quarters · filed 2024-05-09 | $460.74K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $118.65K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $256.01K derived: sum of 2 quarters · filed 2024-03-21 | $391.88K derived: sum of 3 quarters · filed 2024-03-21 | $511.48K 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $137.36K 10-Q · filed 2023-11-09 | $273.23K derived: sum of 2 quarters · filed 2023-11-09 | $392.83K 10-Q · filed 2023-11-09 | $505.93K derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $135.87K 10-Q · filed 2023-08-10 | $255.47K 10-Q · filed 2023-08-10 | $368.56K derived: sum of 3 quarters · filed 2023-08-10 | $479.70K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $119.59K 10-Q · filed 2023-05-11 | $232.69K derived: sum of 2 quarters · filed 2023-05-11 | $343.83K derived: sum of 3 quarters · filed 2023-05-11 | $453.75K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $113.10K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $224.23K derived: sum of 2 quarters · filed 2023-03-22 | $334.15K derived: sum of 3 quarters · filed 2023-03-22 | $410.44K 10-K · filed 2023-03-22 | ||
| 2021-09-30 | $111.13K 10-Q · filed 2022-11-09 | $221.05K derived: sum of 2 quarters · filed 2022-11-09 | $297.34K 10-Q · filed 2022-11-09 | $378.12K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $109.92K 10-Q · filed 2022-08-11 | $186.21K 10-Q · filed 2022-08-11 | $266.99K derived: sum of 3 quarters · filed 2022-08-11 | $377.79K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $76.28K 10-Q · filed 2022-05-12 | $157.07K derived: sum of 2 quarters · filed 2022-05-12 | $267.87K derived: sum of 3 quarters · filed 2022-05-12 | $379.60K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $80.78K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $191.58K derived: sum of 2 quarters · filed 2022-03-22 | $303.32K derived: sum of 3 quarters · filed 2022-03-22 | $468.91K 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $110.80K 10-Q · filed 2021-11-12 | $222.53K derived: sum of 2 quarters · filed 2021-11-12 | $388.13K 10-Q · filed 2021-11-12 | $511.12K derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $111.73K 10-Q · filed 2021-08-12 | $277.33K 10-Q · filed 2021-08-12 | $400.32K derived: sum of 3 quarters · filed 2021-08-12 | $632.75K derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $165.60K 10-Q · filed 2021-05-11 | $288.58K derived: sum of 2 quarters · filed 2021-05-11 | $521.02K derived: sum of 3 quarters · filed 2021-05-11 | $755.17K derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $122.99K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $355.42K derived: sum of 2 quarters · filed 2021-03-16 | $589.58K derived: sum of 3 quarters · filed 2021-03-16 | $806.09K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $232.44K 10-Q · filed 2020-11-12 | $466.59K derived: sum of 2 quarters · filed 2020-11-12 | $683.10K 10-Q · filed 2020-11-12 | $922.18K derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $234.15K 10-Q · filed 2020-08-12 | $450.67K 10-Q · filed 2020-08-12 | $450.68K 10-Q · filed 2019-08-14 | $689.75K derived: sum of 3 quarters · filed 2020-08-12 | $995.80K derived: sum of 4 quarters · filed 2020-08-12 | |
| 2019-03-31 | $216.51K 10-Q · filed 2020-05-14 | $243.09K 10-Q · filed 2019-05-13 | $455.59K derived: sum of 2 quarters · filed 2020-05-14 | $761.64K derived: sum of 3 quarters · filed 2020-05-14 | $1.19M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | $239.08K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $545.13K derived: sum of 2 quarters · filed 2020-03-26 | $973.31K derived: sum of 3 quarters · filed 2020-03-26 | $1.36M 10-K · filed 2020-03-26 | ||
| 2018-09-30 | $306.05K 10-Q · filed 2019-11-14 | $734.23K derived: sum of 2 quarters · filed 2019-11-14 | $1.12M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $428.18K 10-Q · filed 2019-08-14 | $816.95K 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | $383.85K 10-Q · filed 2019-05-13 | |||||
| 2013-12-31 | $431.50K 10-K · filed 2015-07-20 | |||||
| 2012-12-31 | $339.78K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |